PI3K/Akt/mTOR and Raf/MEK/ERK signaling pathways perturbations in non-functioning pituitary adenomas.

Endocrine
H Rubinfeld, I Shimon

Abstract

Non-functioning pituitary adenomas (NFPAs) comprise a heterogeneous group, which are considered the most common pituitary tumor. As no clinically hormone hypersecretion is apparent, non-functioning pituitary adenomas are often diagnosed only when they are large enough to cause tumor mass effects, such as hypopituitarism, visual field defects or headaches. Efficient medical therapy for NFPAs is currently unavailable and surgical treatment of these tumors is not always satisfactory. Characterization of signaling regulatory events in the context of NFPAs may enable the development of new attractive novel strategies. Although data regarding gene expression profiling of signaling pathways in NFPAs have accumulated, studies aimed at fine-classification of NFPAs-specific signaling regulatory mechanisms and feedback loops are scarce.

References

Nov 1, 1992·The Journal of Clinical Endocrinology and Metabolism·T W de BruinR J Croughs
Jul 1, 1993·Journal of Endocrinological Investigation·M GasperiE Martino
Feb 1, 1996·The Journal of Clinical Endocrinology and Metabolism·V K LeRicheS Ezzat
Jan 1, 1996·Annual Review of Medicine·Y Greenman, S Melmed
Dec 10, 1998·The Journal of Endocrinology·M L Jaffrain-ReaA Gulino
Mar 17, 2000·The Journal of Clinical Endocrinology and Metabolism·H E TurnerJ A Wass
Jun 28, 2000·European Journal of Endocrinology·S JordanA B Grossman
Jul 3, 2002·Nature Reviews. Cancer·Igor Vivanco, Charles L Sawyers
Jul 20, 2002·The International Journal of Biochemistry & Cell Biology·Pier Paolo Di Fiore, Giorgio Scita
Jan 8, 2003·The Journal of Cell Biology·Metello InnocentiGiorgio Scita
Nov 7, 2003·The Journal of Clinical Endocrinology and Metabolism·Xun ZhangAnne Klibanski
Jan 13, 2005·The Journal of Clinical Endocrinology and Metabolism·Jing ZhaoAnne Klibanski
Jun 11, 2005·Endocrine-related Cancer·M MusatA B Grossman
Nov 17, 2005·Oncogene·Deborah A Altomare, Joseph R Testa
Nov 29, 2005·Endocrine·Maria A TichomirowaAlbert Beckers
Feb 3, 2006·Cancer Research·Kathryn E O'ReillyNeal Rosen
May 9, 2006·Nature·Lloyd C TrotmanPier Paolo Pandolfi
Jul 27, 2006·European Journal of Endocrinology·Erika HubinaMárta Korbonits
Feb 17, 2007·Clinical Endocrinology·Iain EwingAshley B Grossman
Dec 15, 2007·Endocrinology·Marianne S ElstonKerrie L McDonald
Aug 5, 2008·Cancer Research·George VlotidesShlomo Melmed
Sep 11, 2008·Endocrine-related Cancer·Annamaria ColaoSilvia Savastano
Sep 17, 2008·Oncogene·Y Yin, W H Shen
Oct 15, 2008·Endocrine-related Cancer·Yong LinYuan Lu
Feb 12, 2009·Journal of Molecular Endocrinology·K J DudleyW E Farrell
May 7, 2009·Hormone Research·Márta Korbonits, Eivind Carlsen

❮ Previous
Next ❯

Citations

Feb 5, 2013·Endocrine·Federica GuaraldiSilvia Grottoli
Jul 19, 2012·Clinical Endocrinology·Andrea Giustina
Oct 7, 2015·Frontiers in Endocrinology·Fabio GrizziAntonio Di Ieva
Jul 29, 2016·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Kai ZhouDangmurenjiafu Geng
Mar 4, 2017·Journal of Neuro-oncology·Xiaohui YaoYazhuo Zhang
Feb 7, 2018·Pituitary·Maria Chiara Zatelli
Nov 2, 2014·Molecular Endocrinology·Allyson BoothArthur Gutierrez-Hartmann
Jun 14, 2019·Frontiers in Endocrinology·Congxin DaiRenzhi Wang
Jun 25, 2019·Frontiers in Endocrinology·Miaolong LuXianquan Zhan
Oct 19, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mari C Vázquez-BorregoRaúl M Luque

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.